[CAS NO. ] MifamurtideTFA

Name: MifamurtideTFA
Brand: Arctom Scientific
SKU: HY-13682C

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS

Store

Catalog

HY-13682C

Brand

MCE

CAS

-

DESCRIPTION

Overview

MDL	-
Molecular Weight	1351.52
Molecular Formula	C61H110F3N6O21P
SMILES	CCCCCCCCCCCCCCCC(OC[C@@H](OC(CCCCCCCCCCCCCCC)=O)COP(OCCNC([C@@H](NC(CC[C@@H](NC([C@@H](NC([C@H](O[C@]([C@H](O)[C@H](O)CO)([H])[C@@H](NC(C)=O)C=O)C)=O)C)=O)C(N)=O)=O)C)=O)(O)=O)=O.OC(C(F)(F)F)=O

For research use only. We do not sell to patients.

Summary

Mifamurtide TFA (MTP-PE TFA), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide TFA, an orphan drug, is a specific ligand of NOD2 used as an insulin sensitizer. Mifamurtide TFA has the potential for osteosarcoma research ^[1] ^[2] ^[3] .

IC50 & Target

NOD2

In Vitro

Mifamurtide TFA (MTP-PE TFA; 100 µM) induces a reduction of MG63 cells number when co-cultured with macrophages ^[3] .
Mifamurtide TFA (100 µM) increases both the M1 polarization marker iNOS and the M2 polarization marker CD206 mRNAs; both pro-inflammatory (IL-1β, IL-6) and anti-inflammatory (IL-4, IL-10) cytokines. Mifamurtide TFA increases the iron transporter DMT1 protein ^[3] .
L-mifamurtide TFA (5, 5000 nM; for 48 hours) alone has no direct effect on the proliferation rate of the two osteosarcoma cell lines MOS-J and KHOS in vitro or in vivo ^[1] .
Mifamurtide TFA acts as a nonspecific immunomodulator by activating macrophages and monocytes related to the upregulation of tumoricidal activity and secretion of pro-inflammatory cytokines including tumor necrosis factor (TNF)-a, interleukin (IL)-1, IL-6, IL-8, IL-12, nitric oxide (NO), prostaglandin E2 (PGE2) and PGD2 ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mifamurtide TFA (MTP-PE TFA; 1 mg/kg; i.v.; twice per week for 4 weeks) causes a trend of diminished spontaneous lung metastasis dissemination ^[1] .
Mifamurtide TFA (50 μg/mouse) improves glucose tolerance during endotoxemia in mice. Mifamurtide TFA (equivalent to 20 μg MDP; 4 times per week for 5 weeks) improves glucose tolerance in HFD-fed mice without altering body mass ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6, BALB/c mice with KHOS osteosarcoma cells ^[1]
Dosage:	1 mg/kg
Administration:	IV; twice per week for 4 weeks
Result:	Caused a trend of diminished spontaneous lung metastasis dissemination in xenogeneic (KHOS) and syngeneic (MOS-J) models.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03643133	UNICANCER	Osteosarcoma	October 23, 2018	Phase 2
NCT02441309	University of Oxford\|Millennium: The Takeda Oncology Company\|National Institute for Health Research, United Kingdom\|Oxford University Hospitals NHS Trust\|European Commission	Osteosarcoma	October 2014	Phase 2
NCT00631631	Millennium Pharmaceuticals, Inc.	Osteosarcoma	January 2008
NCT04571229	Memorial Sloan Kettering Cancer Center	Osteosarcoma
NCT01194284	Millennium Pharmaceuticals, Inc.\|Takeda	Osteosarcoma	December 2011
NCT01459484	Italian Sarcoma Group	Osteosarcoma	June 23, 2011	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL ( 18.50 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.7399 mL	3.6995 mL	7.3991 mL
5 mM	0.1480 mL	0.7399 mL	1.4798 mL
10 mM	0.0740 mL	0.3700 mL	0.7399 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (1.85 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (1.85 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (1.85 mM); Clear solution

* All of the co-solvents are available by MCE.